Results 81 to 90 of about 7,117 (221)

A phase II study of Bruton’s tyrosine kinase inhibition for the prevention of anaphylaxis

The Journal of Clinical Investigation, 2023
BACKGROUND IgE-mediated anaphylaxis is a potentially fatal systemic allergic reaction for which there are no currently FDA-approved preventative therapies.
Ragha V. Suresh, Collin Dunnam, Dhananjay Vaidya, Robert A. Wood, Bruce S. Bochner, Donald W. MacGlashan Jr., Melanie C. Dispenza   +6 more
doaj   +1 more source

Tonic signaling of the B‐cell antigen‐specific receptor is a common functional hallmark in chronic lymphocytic leukemia cell phosphoproteomes at early disease stages

Molecular Oncology, Volume 19, Issue 12, Page 3706-3728, December 2025.
B‐cell chronic lymphocytic leukemia (B‐CLL) and monoclonal B‐cell lymphocytosis (MBL) show altered proteomes and phosphoproteomes, analyzed using mass spectrometry, protein microarrays, and western blotting. Identifying 2970 proteins and 316 phosphoproteins, including 55 novel phosphopeptides, we reveal BCR and NF‐kβ/STAT3 signaling in disease ...
Paula Díez, Pablo Juanes‐Velasco, Marina L. García‐Vaquero, Conrad Droste, Alicia Landeira‐Viñuela, Miguel Alcoceba, Helena Fidalgo‐Gómez, Sara Misiego‐Herrero, Almudena Navarro‐Bailón, Mónica Baile, José M. Bastida, Jose Manuel Sanchez‐Santos, Rafael Góngora, Julia Almeida, Marcos Gonzalez‐Diaz, Alberto Orfao, Javier De Las Rivas, Manuel Fuentes   +17 more
wiley   +1 more source

Healthcare Resource Utilization and Costs in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia Treated With Covalent Bruton's Tyrosine Kinase Inhibitors: Real‐World Impact of Cardiovascular Adverse Events

Cancer Medicine, Volume 14, Issue 24, December 2025.
ABSTRACT Introduction Although covalent Bruton's tyrosine kinase inhibitors (cBTKis) have transformed treatment of chronic lymphocytic leukemia and small lymphocytic leukemia (CLL/SLL), cBTKi‐related cardiotoxicity is a known side effect. This real‐world study evaluated incident cardiovascular adverse events (CVAE), healthcare resource utilization ...
Mavis Obeng‐Kusi, Enrico De Nigris, Siyang Leng, Mohammed Z. H. Farooqui, Halit O. Yapici, Ian Weimer, Weiqi Jiao, Hayden W. Hyatt, Xuan Zhang, Kunal Lodaya, David Dingli   +10 more
wiley   +1 more source

Cost-effectiveness analysis of acalabrutinib in treatment of patients with relapsed/refractory form of mantle cell lymphoma who previously received at least one line of therapy

Фармакоэкономика
Objective: to conduct a clinical and economic study of acalabrutinib for the treatment of adult patients with relapsed/refractory form of mantle cell lymphoma who previously received at least one line of therapy in the Russian Federation.Material and ...
S. K. Zyryanov, I. N. Dyakov
doaj   +1 more source

Acalabrutinib Approved for MCL [PDF]

Cancer Discovery, 2018
Abstract The FDA granted accelerated approval to the second-generation BTK inhibitor acalabrutinib, which, because of its increased selectivity, seems to cause fewer side effects than ibrutinib, previously the only BTK inhibitor on the market.
openaire   +2 more sources

Real-World Comparison of First-Line Treatment Adherence Between Single-Agent Ibrutinib and Acalabrutinib in Patients with Chronic Lymphocytic Leukemia

Patient Preference and Adherence, 2023
Xiaoxiao Lu,1 Bruno Emond,2 Laura Morrison,2 Frederic Kinkead,2 Patrick Lefebvre,2 Marie-Hélène Lafeuille,2 Wasiulla Khan,1 Linda H Wu,1 Zaina P Qureshi,1 Ryan Jacobs3 1Real World Value and Evidence, Oncology, Janssen Scientific Affairs, LLC, Horsham, PA,
Lu X, Emond B, Morrison L, Kinkead F, Lefebvre P, Lafeuille MH, Khan W, Wu LH, Qureshi ZP, Jacobs R   +9 more
doaj  

Functional differences between CLL‐ and ALL‐derived CAR T cells in a 3D tumor microenvironment highlight CXCR4 and IL‐10 as potential modulatory targets

HemaSphere, Volume 9, Issue 12, December 2025.
Abstract Despite advances in targeted therapies, treatment of chronic lymphocytic leukemia (CLL) remains challenging, highlighting the urgent need for effective new therapeutic strategies. Although chimeric antigen receptor (CAR) T‐cell therapy dramatically improved outcomes in acute lymphoblastic leukemia (ALL), its efficacy in CLL is limited.
Janin Dingfelder, Michael Aigner, Jana Lindacher, Pascal Lukas, Cindy Flamann, Gina Nusser, Katharina Zimmermann, Axel Schambach, Frederik Graw, Simon Völkl, Heiko Bruns, Manuela Krumbholz, Martina Haibach, Jochen Wilke, Andreas Mackensen, Gloria Lutzny‐Geier   +15 more
wiley   +1 more source

Identifying Risk Factors for Anxiety and Depression in Patients with Chronic Lymphocytic Leukemia [PDF]

, 2018
Pelatonia Fellowship Program AwardThe American Society of Clinical Oncology (ASCO) has provided risk factors (past psychiatric history, gender, low SES, additional chronic illness, and martial status) for greater anxiety (GAD-7) and depressive (PHQ-9 ...
Robbertz, Abigail
core  

Acalabrutinib-based regimens in frontline or relapsed/refractory higher-risk CLL: Pooled analysis of 5 clinical trials [PDF]

: Before targeted therapies, patients with higher-risk chronic lymphocytic leukemia (CLL) defined as del(17p) and/or TP53 mutation (TP53m), unmutated immunoglobulin heavy chain variable region genes (uIGHV), or complex karyotype (CK) had poorer prognosis
Butturini, Anna Maria, Byrd, John C, Davids, Matthew S, Emeribe, Ugochinyere, Eyre, Toby A, Ghia, Paolo, Jurczak, Wojciech, Palhares de Miranda, Paulo A, Shahkarami, Mina, Sharman, Jeff P, Siddiqi, Tanya, Woyach, Jennifer A   +11 more
core   +1 more source

The Direction of Modern Therapies in Waldenström Macroglobulinaemia

Journal of Cellular and Molecular Medicine, Volume 29, Issue 24, December 2025.
ABSTRACT Waldenström macroglobulinaemia (WM) is a rare lymphoplasmacytic disease that is hallmarked by B‐cell infiltration of the bone marrow, an overexpression of IgM class antibodies and an activating mutation of MYD88 (L265P). The therapeutic options for WM patients include a combination of Rituximab (anti‐CD20 monoclonal antibody) and chemotherapy,
Stephen Blackmore, Sherine Elsawa, Omid Tavana   +2 more
wiley   +1 more source